 LONDON, UK ACCESSWIRE December 5, 2019 Midatech Pharma PLC Midatech or the Company AIM:MTPH.L; Nasdaq:MTP, an RD; biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that it has received confirmation of a 2.6 million EU grant to be used to conduct a ground-breaking clinical study, GlioKIDS, designed to demonstrate the efficacy of MTX110 as a treatment for Diffuse Intrinsic Pontine Glioma DIPG, a rare and fatal form of childhood brain cancer with an average life expectancy of 7 to 9 months. The grant is under the EU EIC Accelerator SME Instrument and is part of the European Innovation Council EIC that supports top class innovators and small companies with funding opportunities to establish market-creating innovations that shape new markets and generate jobs, growth and higher standards of living. 